The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial
Patrick A. Zweidler‐McKay(The University of Texas MD Anderson Cancer Center), Bruce S. Fischer(Bristol-Myers Squibb (United States)), Norbert Vey(Centre de Recherche en Cancérologie de Marseille), Oliver G. Ottmann(Cardiff University), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Gaurav Bajaj(Bristol-Myers Squibb (United States)), Fei Huang(Bristol-Myers Squibb (United States)), Hervé Dombret(University of London Institute in Paris), Dan Douer(Memorial Sloan Kettering Cancer Center), Deborah A. Thomas(Washington University in St. Louis)
Cited by 48
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k